Cargando…
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908025/ https://www.ncbi.nlm.nih.gov/pubmed/36753549 http://dx.doi.org/10.1126/sciadv.abq7459 |
_version_ | 1784884298092904448 |
---|---|
author | Wang, Yazhe Malik, Shipra Suh, Hee-Won Xiao, Yong Deng, Yanxiang Fan, Rong Huttner, Anita Bindra, Ranjit S. Singh, Vijender Saltzman, W. Mark Bahal, Raman |
author_facet | Wang, Yazhe Malik, Shipra Suh, Hee-Won Xiao, Yong Deng, Yanxiang Fan, Rong Huttner, Anita Bindra, Ranjit S. Singh, Vijender Saltzman, W. Mark Bahal, Raman |
author_sort | Wang, Yazhe |
collection | PubMed |
description | Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs. |
format | Online Article Text |
id | pubmed-9908025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-99080252023-02-09 Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy Wang, Yazhe Malik, Shipra Suh, Hee-Won Xiao, Yong Deng, Yanxiang Fan, Rong Huttner, Anita Bindra, Ranjit S. Singh, Vijender Saltzman, W. Mark Bahal, Raman Sci Adv Biomedicine and Life Sciences Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs. American Association for the Advancement of Science 2023-02-08 /pmc/articles/PMC9908025/ /pubmed/36753549 http://dx.doi.org/10.1126/sciadv.abq7459 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Wang, Yazhe Malik, Shipra Suh, Hee-Won Xiao, Yong Deng, Yanxiang Fan, Rong Huttner, Anita Bindra, Ranjit S. Singh, Vijender Saltzman, W. Mark Bahal, Raman Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title_full | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title_fullStr | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title_full_unstemmed | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title_short | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy |
title_sort | anti-seed pnas targeting multiple oncomirs for brain tumor therapy |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908025/ https://www.ncbi.nlm.nih.gov/pubmed/36753549 http://dx.doi.org/10.1126/sciadv.abq7459 |
work_keys_str_mv | AT wangyazhe antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT malikshipra antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT suhheewon antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT xiaoyong antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT dengyanxiang antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT fanrong antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT huttneranita antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT bindraranjits antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT singhvijender antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT saltzmanwmark antiseedpnastargetingmultipleoncomirsforbraintumortherapy AT bahalraman antiseedpnastargetingmultipleoncomirsforbraintumortherapy |